Teva: Maximum Pessimism - Teva Pharmaceutical Industries Limited (NYSE:TEVA) | Seeking Alpha
Questa è di ieri:
Teva Pharmaceutical Industries has come out on the short end of an appeals court ruling on three patents covering weight-loss pill
Contrave (naltrexone HCl and bupropion HCl).
In a 2-1 decision, the court upheld one patent that expires in 2030 but invalidated two others that expire in 2024 and 2025. Unfortunately for Teva, it is barred from selling a generic version until all three patents have expired.
Contrave, originally marketed by Takeda (licensed from Orexigen), is now sold by
Nalproprion Pharmaceuticals, a joint venture between Pernix Therapeutics Holdings and certain institutional investors.